Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Relief of Migraine Pain Through Electro Stimulation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Siano Mobile Silicon
ClinicalTrials.gov Identifier:
NCT02453399
First received: May 13, 2015
Last updated: May 24, 2016
Last verified: May 2016
  Purpose
This study will evaluate transcutaneous electro stimulation device developed by Siano for adequacy, safety and efficacy for the treatment and/or prevention of migraine pain for migraine sufferers.

Condition Intervention
Migraine Headache
Device: Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Relief of Migraine Pain Through Transcutaneous Electro Stimulation

Resource links provided by NLM:


Further study details as provided by Siano Mobile Silicon:

Primary Outcome Measures:
  • Migraine relief at 2 hours post treatment as determined by difference of reported pain levels at the beginning and 2 hours after the end of electro stimulation session. Pain levels are assessed by means of Numerical Pain Scale. [ Time Frame: 2.5 hours ]
  • Relative migraine pain relief at 2 hours post treatment [ Time Frame: 2.5 hours ]
    Relative migraine pain relief at 2 hours post treatment as determined by difference of reported pain levels at the beginning and 2 hours after the end of electro stimulation session normalized by pain level on start of the session. Pain levels are assessed by means of Numerical Pain Scale.

  • Percent responders resulted in significant pain relief at 2 hours post treatment [ Time Frame: 2.5 hours ]
    Percent of responders with improvement of 50% or better in pain level according to NPS


Secondary Outcome Measures:
  • Migraine attack duration as determined by time between reported onset of migraine attack and time when, for this attack, reported pain level drops by at least three levels. Pain levels are assessed by means of Visual Analog Scale . [ Time Frame: 2.5 hours ]
  • Use of pain relief medications as assessed by participants' reports at follow-up. [ Time Frame: 6 months ]
    Use of pain relief medications, including dosage

  • Number of migraine attacks per month as determined by the number of activations. [ Time Frame: 6 months ]
  • Overall wellbeing as assessed by means of post-study questionnaire [ Time Frame: 6 months ]
  • Treatment related adverse effects, as assessed by means of post-study questionnaire, or participants' reports during the study. [ Time Frame: 6 months ]
  • Migraine Relief at end of treatment as determined by difference of reported pain levels at the beginning of the electro stimulation and in the end of the electro stimulation session. Pain levels are assessed by means of NPS . [ Time Frame: 0.5 hours ]

Enrollment: 87
Study Start Date: July 2015
Study Completion Date: May 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.
    Transcutaneous electro stimulation
Detailed Description:

This study will gather information regarding performance of Avital transcutaneous electro stimulation device developed by Siano. Electrostimulation in the form of weak electrical pulses arranged in specific patterns (programs), is delivered through adhesive electrodes attached to patient's skin. A set of stimulation programs, out of which one is placebo, is stored in device memory.The device is controlled wirelessly using a dedicated smartphone application. Participants will be instructed to attach and activate the device at the onset of a migraine attack and manually adjust stimulation intensity to a level where it is perceivable but not painful. Upon each activation, a program will be automatically picked for execution in random order. Randomization is performed within and between subjects. Subjects will not be aware of the executed program. Subjects are requested to refrain from use of migraine relief drugs prior to treatment and during the first two hours of the treated attack. Throughout the course of electrostimulation, participants will be requested to rate their migraine pain level via te same smartphone application, using Visual Analog Scale (VAS).

Overall experimental duration for each participant will be determined by the goal of using the Avital device for 10-20 migraine attacks.

Data containing activation times, executed programs, stimulation intensity and user feedback will be transmitted via the smartphone to a central database for analysis. All data are completely de-identified and linked to a unique code assigned to each device. The link between participant's ID and this code will be securely maintained by the research coordinator. Database will be overseen by Siano staff responsible for monitoring the clinical study. The electronic database will be used to generate outcome measures.

In the course of this study the investigators will obtain controlled data on the safety and efficacy of transcutaneous electro stimulation for migraine treatment using Siano developed transcutaneous electro stimulation device.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Matches International Headache Society criteria for migraine with and without aura
  • Reports 2-8 migraine attacks per month

Exclusion Criteria:

  • Has other significant pain problem (e.g.cancer pain, fibromyalgia or other head or facial disorder) that in the opinion of the investigator may confound the study assessments
  • Has severe cardiac or cerebrovascular disease
  • Has uncontrolled high blood pressure (systolic >160 diastolic > 100 after 3 repeated measurements within 24 hours)
  • Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator)
  • Known epilepsy
  • Use of Cannabis including medical use.
  • Has chronic migraine (more than 15 headache days per month).
  • Has undergone nerve block (occipital or other) in the head or neck within the last 2 months.
  • Has received Botox injections within the last 6 months.
  • Is pregnant or thinking of becoming pregnant during the study period, or of childbearing years and is unwilling to use an accepted form of birth control.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02453399

Locations
Israel
Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Siano Mobile Silicon
Investigators
Principal Investigator: David Yarnitsky, MD Rambam Health Care Campus
  More Information

Responsible Party: Siano Mobile Silicon
ClinicalTrials.gov Identifier: NCT02453399     History of Changes
Other Study ID Numbers: RMB001115
Study First Received: May 13, 2015
Last Updated: May 24, 2016

Additional relevant MeSH terms:
Migraine Disorders
Headache
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pain
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on May 25, 2017